These observations show that only Panobinostat and Belinostat strong activate anti-cancer effects on breast cancer cells, with superior cell growth inhibition and cell death induction in MDA-MB-231 and SK-BR-3 cells, indicating these drugs may be used as therapeutic drugs in TNBC and HER2-enrich breast cancer subtypes. Here, ERBB2 is linked to cancer.